Risk of hypoglycaemia with insulin degludec versus insulin glargine U300 in insulin-treated patients with type 2 diabetes: the randomised, head-to-head CONCLUDE trial.
Athena Philis-TsimikasDavid C KlonoffKamlesh KhuntiHarpreet S BajajLawrence A LeiterMelissa V HansenLone N TroelsenSteen LadelundSimon HellerThomas R Piebernull nullPublished in: Diabetologia (2020)
ClinicalTrials.gov NCT03078478 FUNDING: This trial was funded by Novo Nordisk (Bagsvaerd, Denmark).